[ad_1]
DUBLIN – (COMMERCIAL THREAD) – The report “Human Papillomavirus 16 – positive (HPV16 +) Cancers – Market Insight, Epidemiology and Market Forecast – 2030” has been added to ResearchAndMarkets.com offer.
This report provides an in-depth understanding of HPV 16+ cancer, historical and predicted epidemiology as well as market trends in the US, EU5 (Germany, France, Italy, Spain and UK) and Japan .
HPV 16+ Cancer Market report provides current treatment practices, emerging drugs, individual therapies market share, current and forecasted HPV 16+ Cancer Symptoms market size from 2018 to 2030, segmented by seven main markets. The report also covers the current HPV 16+ Cancer Symptom Treatment Practice / Algorithm, Market Drivers, Market Barriers, and Unmet medical need to arrange best opportunities. It assesses the underlying potential of the market.
Companies mentioned
-
Advaxis, Inc.
-
BioNTech
-
Cue Biopharma
-
GlaxoSmithKline
-
Hookipa Pharmacy
-
Innovio Pharma
-
Invectys
-
ISA Pharmaceutical
-
Merck
-
PDS Biotechnology
-
Precigen
-
Regeneron Pharmaceuticals
-
Roche Pharma SA
-
Transgene
-
AS vaccine
Scope of the report
-
The report covers the descriptive overview of HPV 16+ cancer, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies.
-
A comprehensive overview was provided on the epidemiology and treatment of HPV 16+ cancer in the US, EU5 (Germany, Spain, France, Italy, UK) and Japan
-
Additionally, a comprehensive account of current and emerging therapies for HPV 16+ cancer is provided, as well as the assessment of new therapies, which will impact the current therapeutic landscape.
-
A detailed review of the HPV 16+ cancer market; history and forecast are included in the report, covering drug awareness in US, EU5 (Germany, Spain, France, Italy, UK) and Japan
-
The report provides advantage while developing business strategies by understanding the trends shaping and driving the global HPV 16+ cancer market
Reasons to buy
-
The report will help develop business strategies by understanding the trends shaping and driving the HPV 16+ cancer market.
-
To understand the future competition in the HPV 16+ cancer market and an in-depth look at the key drivers and barriers in the market
-
Organize sales and marketing efforts by identifying the best opportunities for HPV 16+ cancer in the US, EU5 (Germany, Spain, France, Italy, UK) and Japan
-
Identifying strong future players in the market will help design strategies that will help get ahead of competitors
-
To organize sales and marketing efforts by identifying the best opportunities for the HPV 16+ Cancer market
-
Understanding the future competition in the HPV 16+ cancer market
Main topics covered:
1. Key information
2. Presentation of the report
3. HPV16 + Cancer Market Overview at a Glance
3.1. Market share (%) Distribution of HPV16 + cancer in 2018
3.2. Market share (%) Distribution of HPV16 + cancer in 2030
4. Executive summary of HPV16 + cancer
5. Background and overview of the disease
5.1. introduction
5.2. Etiology
5.3. Risk factors
5.4. Molecular mechanisms of HPV
5.5. Malignancies associated with HPV
5.6. HPV and cancer progression
5.7. Diagnostic
5.8. Biomarkers
6. Epidemiology and patient population
6.1. Main conclusions
6.2. Hypothesis and justification
6.3. Total population of 7 MM of patients with HPV-induced cancer
6.4. United States
6.4.1. Incident cases of HPV-induced cancer in the United States
6.5. UE5
6.5.1. Germany
6.5.1.1. Incident cases of HPV-induced cancer in Germany
6.5.2. France
6.5.2.1. Incident cases of HPV-induced cancer in France
6.5.3. Italy
6.5.3.1. Incident cases of HPV-induced cancer in Italy
6.5.4. Spain
6.5.4.1. Incident cases of HPV16 + cancer in Spain
6.5.5. UK
6.5.5.1. Incident cases of HPV-induced cancer in the UK
6.6. Japan
6.6.1. Incident cases of HPV-induced cancer in Japan
7. Treatment and management
7.1. HPV vaccines
8. Organizations contributing to HPV16 + cancer
9. Patient journey
10. Case reports
11. Marketed products
11.1. Gardasil: Merck
11.1.1. Product Description
11.1.2. Action mechanism
11.1.3. Regulatory milestones
11.1.4. Side effects of Gardasil
11.1.5. Product profile
11.2. Gardasil 9: Merck
11.2.1. Product Description
11.2.2. Regulatory milestones
11.2.3. Safety and effectiveness of Gardasil 9
11.2.4. Side effects of Gardasil 9
11.2.5. Product profile
11.3. Cervarix: GlaxoSmithKline
11.3.1. Product Description
11.3.2. Regulatory milestones
11.3.3. Safety and effectiveness of Cervarix
11.3.4. Side effects of Cervarix
11.3.5. Product profile
12. Emerging therapies
13. Cancer HPV16 +: seven major market analyzes
13.1. Main conclusions
13.2. HPV16 + Cancer Market Size in 7MM
14. Market outlook
15. Market drivers
16. Market barriers
17. SWOT analysis
18. Unmet needs
19. Market access and reimbursement
20. Annex
21. Editor skills
22. Disclaimer
23. About the publisher
For more information on this report, visit https://www.researchandmarkets.com/r/z0asqs
Source link
